IP Library Granted Patent US 9,822,345
Granted Patent B2
US 9,822,345 · App. 15/013,079 · Granted Nov 21, 2017

Method of making a virus using duck embryonic derived stem cell lines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,822,345
App. No.
15/013,079
Granted
Nov 21, 2017
Kind
B2
Abstract

The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.

Claims (41)

1. A method of producing a virus, the method comprising:

a) isolating a duck embryo around oviposition;

b) dissociating the embryo of step a) into cells;

c) seeding the dissociated cells of step b) in basal medium comprising insulin like growth factor 1 (IGF-1), ciliary neurotrophic factor (CNTF), animal serum, and a layer of feeder cells;

d) culturing the cells of step c) for at least one passage;

e) withdrawing the IGF-1 and CNTF from the culture of step d);

f) culturing the cells of step e) for at least one passage;

g) progressively withdrawing the feeder cells from the culture of step f);

h) culturing the cells of step g) for at least one passage;

i) progressively withdrawing the animal serum from the culture medium of step h) over several passages;

j) adapting the cells of step i) to suspension culture conditions such that a duck cell line capable of proliferating in basal medium in the absence of exogenous growth factors, a feeder layer, and animal serum is obtained, wherein the duck cell line does not produce replication-competent endogenous retrovirus particles;

k) proliferating the duck cell line obtained in step j) in a serum-free medium;

l) infecting the duck cell line of step k) with said virus;

m) culturing said infected cells of step l) to allow virus replication; and

n) harvesting said virus.

2. The method of claim 1 , further comprising adding glutamine and D-glucose to the medium of steps k), l), and m).

3. The method of claim 2 , wherein the adding glutamine and D-glucose to the medium of steps k), l), and m) occurs on a daily basis.

4. The method according to claim 2 , wherein the glutamine concentration is maintained between 1 mM to 3 mM, preferably around 2 mM.

5. The method according to claim 2 , wherein the D-glucose concentration in the culture medium of steps k), l), and m) is maintained between 1 g/l to 10 g/l, preferably around 2 to 3 g/l.

6. The method of claim 1 , wherein the cell density in step l) is of at least 1.5 million cells/ml.

7. The method of claim 1 , wherein steps k), l), and m) are performed in a cultivation vessel that is a continuous stirred tank bioreactor.

8. The method of claim 1 , further comprising adding glutamine and D-glucose to the medium of steps l) and m).

9. The method of claim 1 , further comprising adding glutamine and D-glucose to the medium of step l).

10. The method of claim 1 , further comprising adding a proteolytic enzyme to the culture medium of step m).

11. The method according to claim 1 , wherein steps k), l), and m) are performed at a temperature of 33° C.

12. The method according to claim 1 , wherein the withdrawal of IGF-1 and CNTF from the culture medium in step e) is performed simultaneously.

13. The method according to claim 1 , wherein said duck is a Pekin duck.

14. The method according to claim 1 , wherein said duck is a Muscovy duck.

15. The method according to claim 1 , wherein said duck cell line is diploid.

16. The method according to claim 1 , wherein the virus is an endogenous avian leucosis virus (ALV-E) or an endogenous avian retrovirus (EAV).

17. The method according to claim 1 , wherein said virus is selected from the group comprising poxviruses, orthomyxoviruses, paramyxoviruses, herpes viruses, hepadnaviruses, adenoviruses, parvoviruses, reoviruses, circoviruses, coronaviruses, flaviviruses, togaviruses, birnaviruses, and retroviruses.

18. The method according to claim 17 , wherein

the poxvirus is selected from the group consisting of Modified Vaccinia Ankara (MVA) virus, Lister-Elstree vaccinia virus, LC16m8 vaccinia virus, CVI78 vaccinia virus, Fowl pox virus, canary pox virus, ALVAC, NYVAC, juncopox virus, mynah pox virus, pigeonpox virus, psittacine pox virus, quail pox virus, sparrow poxvirus, starling pox virus, and Turkey pox virus;

the paramyxovirus is selected from the group consisting of measles virus, mumps virus, rubella virus, Sendai virus, Respiratory Syncythial virus (RSV), human para-influenza types I and III, Rinderpest virus, canine distemper virus, Newcastle disease virus, and duck para-influenza virus;

the orthomyxovirus is selected from the group consisting of human influenza virus, avian influenza virus, swine influenza virus, equine influenza virus, and feline influenza virus;

the togavirus is selected from the group consisting of Sinbis virus, Semliki forest virus, O'nyong'nyong virus, Chikungunya virus, Mayaro virus, Ross river virus, Eastern equine encephalitis virus, Western Equine encephalitis virus, Venezuelan Equine encephalitis virus, and a recombinant togavirus thereof;

the retrovirus is selected from the group consisting of reticulo-endotheliosis virus, duck infectious anemia virus, duck spleen necrosis virus, and a recombinant retrovirus thereof;

the parvovirus is a duck parvovirus;

the adenovirus is selected from the group consisting of fowl adenovirus, goose adenovirus, duck adenovirus, pigeon adenovirus, and a recombinant adenovirus thereof;

the birnavirus is Infectious Bursal Disease virus; or

the flavivirus is selected from the group consisting of Dengue virus, Japanese encephalitis virus, and West Nile virus.

Assignments (6)
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 31, 2026
From: VALNEVA AUSTRIA GMBH; VALNEVA SE; VALNEVA SWEDEN AB
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 075335/0609 →
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: VALNEVA AUSTRIA GMBH; VALNEVA SE; VALNEVA USA, INC.
Reel/Frame 073516/0522 →
PATENT SECURITY AGREEMENT Recorded Oct 20, 2025
From: VALNEVA AUSTRIA GMBH; VALNEVA SE; VALNEVA SWEDEN AB
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 073164/0032 →
SECURITY INTEREST Recorded Mar 4, 2020
From: VALNEVA SE; VALNEVA USA, INC.; VALNEVA AUSTRIA GMBH
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 052016/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2016
From: GUEHENNEUX, FABIENNE; MOREAU, KARINE; ESNAULT, MAGALI; MEHTALI, MAJID
To: VIVALIS SA
Reel/Frame 039498/0882 →
CHANGE OF NAME Recorded Aug 22, 2016
From: VIVALIS SA
To: VALNEVA
Reel/Frame 039498/0958 →